title: Effect of hypertension therapy with the angiotensin-converting enzyme inhibitor lisinopril on hyperandrogenism in women with polycystic ovary syndrome.
abstract: OBJECTIVE
  To investigate the effect of an angiotensin-converting enzyme inhibitor, lisinopril, on serum androgen and sex-hormone-binding globulin (SHBG) levels in hypertensive women with polycystic ovary syndrome (PCOS).
  
  
  METHODS
  Prospective, observational study.
  
  
  METHODS
  Infertility Clinic of the Sani Konukoglu Hospital, Gaziantep, Turkey.
  
  
  METHODS
  Ten hypertensive women with PCOS.
  
  
  METHODS
  Lisinopril, 10 mg/day, for 4 weeks. MAIN OUTCOME MEASURE(S)): Serum levels of gonadotropins, DHEAS, total T, free T, 17 alpha-hydroxyprogesterone (17-OHP), androstenedione, E2, SHBG, TSH, and PRL were determined.
  
  
  RESULTS
  Hypertension treatment with lisinopril (10 mg/day for 4 weeks) resulted in a statistically significant decrease in serum free T levels. However, there was no difference in the SHBG levels.
  
  
  CONCLUSIONS
  Use of lisinopril, an angiotensin-converting enzyme inhibitor, results in decreased free T levels independently of SHBG. It may affect the free T levels by affecting the ovarian renin-angiotensin system.
authors.affiliation: Infertility Unit, Department of Obstetrics and Gynecology, Sani Konukoglu Hospital, Gaziantep, Turkey. bhacihanefioglu@hotmail.com
authors.forename: Burak
authors.initials: B
authors.lastname: Hacihanefioglu
authors.forename: Asli
authors.initials: A
authors.lastname: Somunkiran
authors.forename: Ismet
authors.initials: I
authors.lastname: Mahmutoglu
authors.forename: Alper
authors.initials: A
authors.lastname: Sercelik
authors.forename: Semra
authors.initials: S
authors.lastname: Toptani
authors.forename: Ertan
authors.initials: E
authors.lastname: Kervancioglu
mesh_terms: D000328:Adult; D000735:Androstenedione / Q000097:blood; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology*; D019314:Dehydroepiandrosterone Sulfate / Q000097:blood; D004958:Estradiol / Q000097:blood; D005260:Female; D006062:Gonadotropins / Q000097:blood; D006801:Humans; D017588:Hyperandrogenism / Q000097:blood* / Q000188:drug therapy; D006973:Hypertension / Q000097:blood* / Q000150:complications / Q000188:drug therapy; D017706:Lisinopril / Q000494:pharmacology*; D011085:Polycystic Ovary Syndrome / Q000097:blood* / Q000150:complications; D011374:Progesterone / Q000031:analogs & derivatives* / Q000097:blood; D011388:Prolactin / Q000097:blood; D011446:Prospective Studies; D012738:Sex Hormone-Binding Globulin / Q000378:metabolism; D013739:Testosterone / Q000097:blood; D013972:Thyrotropin / Q000097:blood
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D006062:Gonadotropins; D012738:Sex Hormone-Binding Globulin; C002175:progesterone 17 alpha-hydroperoxide; D013739:Testosterone; D000735:Androstenedione; D011374:Progesterone; D004958:Estradiol; D019314:Dehydroepiandrosterone Sulfate; D011388:Prolactin; D013972:Thyrotropin; D017706:Lisinopril